Table 9.
Study Type | Biological Effects | Cell Lines, Animal Types | Doses | References |
---|---|---|---|---|
In vivo | ↓VEGF, nerve growth factor, ICAM and MMP-9 expression, lymphocyte accumulation, peroxynitrite formation, PARP activation, IkBa phosphorylation, NF-κB translocation | Rats | 10 mg/kg/day orally for 14 days | [217] |
In vivo | ↑capillary perfusion, functional capillary density, survival time | Rabbits | single bolus infusion 4 mL/kg | [219] |
In vivo | ↓NF-κB activity, IL-6, IL-1β, 8-OHdG, 4-HNE, IL-6, γ-H2AX, Bax, cleaved-caspase-3, IL-6, caspase-1, phosphorylated p6 levels | Mice | 50, 100 mg/kg/day orally for 28 days | [220] |
In vivo | ┬NF-κB pathway activity, ↑Nrf2 signaling pathway activity, ↓TNF-α, IL-1β, and IL-6 expression | Mice | 20, 40, 80 mg/kg i.p. injection once | [31] |
↓: decrease, ↑: increase, ┬: inhibit, μg: microgram, μM: micromole, γ-H2AX: γ-H2A histone family member X, 4-HNE: 4-hydroxy-2-nonenal, 8-OHdG: 8-hydroxydeoxyguanosine, Bax: Bcl-2-associated x, i.p.: intraperitoneal, ICAM: intercellular adhesion molecule, IkBa: inhibitory kappa B kinases a, IL-1β: interleukin-1β, IL-6: interleukin-6, kg: kilogram, mg: milligram, mL: milliliter, MMP-9: matrix metalloprotease-9, NF-κB: nuclear factor-κB Nrf2: nuclear factor erythroid 2-related factor 2, PAR: poly-ADP ribose, VEGF: vascular endothelial growth factor.